Quick Takeaways:
- OS Animal Health (OSAH) received USDA feedback on the commercial development pathway for OST-HER2, its gene-edited, Listeria-based cancer immunotherapy for canine osteosarcoma, covering clinical efficacy, safety, non-clinical data and CMC requirements.
- OSAH plans to seek conditional licensure using existing clinical efficacy data across metastasis prevention, metastatic disease control and prevention of amputation. Additional studies are expected to support eventual full licensure.
- OSAH aims for a potential US launch in 2027 and plans to leverage manufacturing progress from OS Therapies’ human osteosarcoma program. OST-HER2 could become the first HER2-targeted therapy for companion animal cancer.
Why It Matters?
OST-HER2’s potential conditional licensure could give OSAH a first-mover advantage in HER2-targeted canine osteosarcoma, an area with limited treatment options. A 2027 launch could establish a differentiated oncology franchise, while validating gene-edited, Listeria-based immunotherapy as a new platform in companion animal cancer.
Source: OS Animal Health
